Ruti Aga: Six Years Banned — Two for the Substance, Four for the Prescription Pad

10 September. That date appears twice in Ruti Aga's career — first as the start of a provisional suspension, then as the start of a six-year ban. The Athletics Integrity Unit's statement on Thursday made the arithmetic plain: two years for the presence violation, four years for tampering. Total six. For a 32-year-old Ethiopian marathoner, that sum settles the final chapter of a career, because the return year will be 2031 and the age 38.

The real story sits in the reason behind the number. A sample taken after winning a half marathon in China in March returned positive. Substance: methylprednisolone. Defence: treatment for a knee injury. Evidence: a prescription issued by a clinic that did not exist, written by a 'doctor' with no medical registration, who claimed to have used 'an old prescription pad from a former workplace' — a pad the clinic explicitly disowned. Three independent verification failures. That is the actual foundation of the four years.

Six years is not one sanction but two joined together: two for the substance, four for the paperwork. And the second part is heavier than the first.

Start with the pharmacology, because this is where the reporting went wrong. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List — not an anabolic steroid (S1), as several reports described it. S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. A road race's testing window opens at 23:59 the day before the race, so a knee injection given days earlier gets caught. The entire case rested on route and timing, not on the substance.

Based on my years of watching and coding marathon fields, Aga's record belongs to what I call the major-runner-up tier: second at Berlin 2026 in 2:18:34, victory at the Tokyo Marathon 2026 in 2:20:40, and three second-place finishes at World Marathon Majors in total. Zero global championship medals. In the depth of Ethiopian women's marathoning, a 2:18 performer is not automatically selected — that context places the severity of the sanction correctly.

The punishment came not from the substance but from the athlete's own defence. Because S9 is prohibited only in-competition, Aga had a legitimate pathway available: documented medical necessity, correct route, correct washout timing. With a certified injury and sound timing, the case could have landed in the no-fault category, ending in a reprimand or a substantially reduced period, and a tampering charge would never have existed. For an athlete with proper management, the scenario was that no case would exist at all.

The prescription chain destroyed that pathway. A family member became the 'doctor', the clinic did not exist, there was no registration, and when the clinic was contacted it denied the pad. The four-year tampering sanction is document-based, and it also drew on statements made in interview — which means the matter went beyond paper.

The knee injury is the root cause; the forged prescription is the symptom that followed. Chronic knee pathology is a known load-bearing failure point in high-volume marathon training, and an injured athlete faces a direct financial pressure to mask pain — appearance fees, sponsor expectations, the next committed race. Glucocorticoids are the cheapest and most available tool under that pressure. Where a squad has no full-time physician and no TUE infrastructure, the solution usually arrives through informal networks — and informal networks forge pads when they are needed. This is a governance failure larger than one athlete's lapse.

The Chinese label-race circuit accelerates it. For East African marathoners, that circuit is a high-appearance-fee, low-risk income tier between Majors. It is also where AIU testing is densest. Two economies — the appearance-fee economy and the testing economy — are colliding in the same races, and Aga is the product of that collision. I do not chase the market; I audit the window until the pattern confesses.

The objection that will inevitably be raised here is one I consider entirely legitimate: six years for a substance with no proven endurance benefit looks disproportionate. Questioning the enforcement gradient against African road runners is fair, and I will state it fairly first: the sanction architecture is standard — two years for a Specified Substance where intent is not proven, four for tampering — but the consequence lands unevenly, because an athlete has no re-entry structure through which to absorb six lost years.

Then look at it the other way. The inequality is not in the sanction; it is in the medical support gap that existed before the sanction. An athlete with a full medical team files a TUE for a knee injection, observes the washout calendar and keeps records. An athlete without that team reaches for an old prescription pad. The rules apply equally to both; the access does not — and the inequality sits at the start of the pipeline, not the end. That is the detour worth watching: Russia taught me that a detour is not noise, it is the first honest signal.

One paradox deserves recording. A forged document is itself circumstantial evidence of concealment intent — yet it did not escalate the presence sanction to four years. The panel treated the two charges separately: substance proven, intent not proven; tampering fully culpable. That structure tells us the 2+4 sum is standard, and it also tells us the panel rejected a no-significant-fault reduction.

Backdating to 10 September is a procedural courtesy, not a discount — provisional suspension time counts against the ban, so nothing is actually shaved off. A CAS appeal route remains open, typically about twenty-one days from the reasoned decision, but document-based tampering findings are rarely overturned. One point to register as a flag rather than a fact: language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention, and a large share of these four years came from interview statements.

Keep the legacy accounting clean. The violation attaches to the March race, so results before that date — including the 2026 Tokyo title — are not automatically annulled absent a finding of earlier use. The March result and its prize money are almost certainly voided, even though the statement does not spell out the scope. It is also worth recording that no Ethiopian federation statement was quoted — only the AIU spoke.

The next enforcement frontier is not detection, it is document verification. Aga's case is not singular; it belongs to a recognisable family: East African road-racing cases where an initial violation is compounded by a fabricated explanation and the sanction doubles. Because one informal medical network serves an entire training cluster, more such cases in the pipeline is the natural expectation.

Three things to watch. First, whether the March result and prize money are formally confirmed as void. Second, whether the investigation reaches the agent or management — the statement names only a family member, and a forged document does not emerge from an athlete's head alone. Third, whether the Ethiopian federation breaks silence on its medical structures, because that is where the repair has to happen. A registration rule is a boundary; a transfer story is what tests it — and this time the testing took six years.

I have no splits from that race, no field strength, no finishing time. So I will not write a single sentence about performance. What I can write is this: a six-year ban at 32, against Ethiopian depth and a documented record, is functionally a lifetime ban. The question is not whether she returns. The question is whether the next injured marathoner who calls an agent will have an option other than a prescription pad.